This article is a correction to:
Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation
Martin Bidlingmaier1*
Beverly M.K. Biller2David Clemmons3
Jens Otto L. Jørgensen4Hiroshi Nishioka5
Yutaka Takahashi6,7- 1Endocrine Laboratory, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany
- 2Neuroendocrine & Pituitary Tumor Clinical Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States
- 3Department of Medicine, University of North Carolina, Chapel Hill, NC, United States
- 4Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark
- 5Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Tokyo, Japan
- 6Department of Diabetes and Endocrinology, Nara Medical University, Kashihara, Japan
- 7Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
A Corrigendum on
Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation.
by Bidlingmaier M, Biller BMK, Clemmons D, Jørgensen JOL, Nishioka H and Takahashi Y (2022) Front. Endocrinol. 13:1040046. doi: .10.3389/fendo.2022.1040046
Incorrect copyright statement
In the published article, there was an error in the Copyright statement of Figure 1. The statement was incorrectly written as “Reproduced with permission (24).”. The corrected statement is “Reproduced from Bentz Damholt et al. (24) under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/). No changes were made to this figure.”
FIGURE 1
Figure 1 Simulated weekly IGF-I SDS levels following dosing with somapacitan (weekly GH [mean dose 2.4 mg]) and somatropin (daily GH [mean dose 0.3 mg]). Dashed line is weekly average IGF-I SDS for somapacitan (-0.09 SDS). Reproduced from Bentz Damholt et al. (24) under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: somapacitan, growth hormone, adult growth hormone deficiency, insulin-like growth factor I, treatment recommendations, pharmacokinetic/pharmacodynamic modelling, long-acting growth hormone
Citation: Bidlingmaier M, Biller BMK, Clemmons D, Jørgensen JOL, Nishioka H and Takahashi Y (2023) Corrigendum: Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation. Front. Endocrinol. 14:1158214. doi: 10.3389/fendo.2023.1158214
Received: 03 February 2023; Accepted: 06 February 2023;
Published: 02 March 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Bidlingmaier, Biller, Clemmons, Jørgensen, Nishioka and Takahashi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Martin Bidlingmaier, TWFydGluLkJpZGxpbmdtYWllckBtZWQudW5pLW11ZW5jaGVuLmRl